TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin†or the "Company†), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a "Common Share†) and, in lieu of Common Shares to certa. ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which did not meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for aTyr investors affected by alleged securities fraud between January 16, 2025, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a stock price decline from $6.03 to $1.02, an 83.2% drop in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - AbbVie Inc. raised its full-year profit forecast due to strong demand for its psoriasis treatment Skyrizi, leading to third-quarter sales that exceeded expectations, although shares fell over 4% in intra-day trading [1] Financial Performance - For the quarter ending in September, AbbVie reported a net revenue increase of 9.1% year-over-year, reaching $15.78 billion, driven by strong sales of Skyrizi and Rinvoq [2] - Adjusted earnings per share for the quarter were $1.86, a decrease from $4.86 a year earlier, but above Bloomberg's consensus estimate of $1.77 [2] Product Performance - The growth in immunology products helped mitigate the decline in Humira, which has faced significant competition from lower-cost biosimilars since 2023 [3] - Rinvoq generated $5.97 billion in revenue in 2024, representing approximately half of AbbVie's total sales, with expectations that Rinvoq and Skyrizi will together contribute about $31 billion in revenue by 2027 [3]

Key Takeaways Agios reported a Q3 loss of $1.78 per share, beating expectations of a loss of $1.93.AGIO's total revenues climbed 44% year over year to $12.9 million, fueled by Pyrukynd sales.The FDA decision on Pyrukynd's thalassemia indication is due on Dec. 7, as the EMA gives a positive opinion.Agios Pharmaceuticals (AGIO) incurred a loss of $1.78 per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.93. In the year-ago quarter, the company had reported earnin ...

Key Takeaways Apellis posted Q3 EPS of $1.67, beating estimates, versus a loss of 46 cents a year ago.Revenues more than doubled to $458.6M, lifted by a $275M upfront payment from Sobi.Syfovre sales fell 1% year over year, missing expectations and weighing on investor sentiment.Apellis Pharmaceuticals (APLS) reported third-quarter 2025 earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. The company had incurred a loss of 46 cents in the year-ago quarter.Total revenues in th ...

Accessibility StatementSkip Navigation WOONSOCKET, R.I., Oct. 31, 2025 /PRNewswire/ -- CVS Pharmacy®Â customers donated more than $3 million this year to support local food banks across the country, and CVS Health® (NYSE: CVS) is boosting the overall contribution to support Feeding America. The in-store campaign, hosted at CVS Pharmacy locations nationwide, gave customers a simple and impactful way to contribute to the movement to end hunger in their own communities. CVS Health has also committed over $2 mi ...

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses due to misleading statements about the drug Efzofitimod [1][2]. Group 1: Class Action Details - The new class action, King v. aTyr Pharma Inc., covers investors who acquired aTyr securities from November 7, 2024, to September 12, 2025, significantly extending the previous class period that began in January 2025 [2][4]. - The lawsuit alleges that aTyr and its executives made false statements regarding the efficacy of Efzofitimod, leading to inflated stock prices [4][7]. Group 2: Allegations and Study Findings - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which aimed to evaluate Efzofitimod's effectiveness in reducing steroid dependency in patients with pulmonary sarcoidosis [5][6]. - Throughout the class period, aTyr executives reportedly expressed confidence in the study's design while allegedly concealing adverse facts about the drug's efficacy [6][7]. Group 3: Market Reaction and Investigation - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a dramatic stock price drop from $6.03 to $1.02, an 83.2% decline in one day [8][9]. - Hagens Berman is investigating whether aTyr misled investors regarding the drug's data and trial design, emphasizing its potential multi-billion-dollar market opportunity [10].

Nexperia has been locked in a dispute with its Chinese unit after the Dutch government took control of Nexperia from its Chinese owner Wingtech on Sept 30.The EU is determined to find a diplomatic solution over the ownership of Dutch chipmaker Nexperia, the European Commission’s tech chief Henna Virkkunen has said.That’s all for today but you can read all the latest business and economic stories from The Telegraph here .Thanks for joining us on this live blog.Chris Beauchamp, an analyst at IG, said: “Next w ...

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.GILD is in positive territory. Get the complete picture hereThe U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and Livdelzi (seladelpar) sales."With multiple potential product launches in 2026, the ...